Definium Therapeutics, Inc. (DFTX) Stock

Definium Therapeutics, Inc. (DFTX) is a Healthcare stock trading at $44.88 (as of 2026-08-21), with a market capitalization of $6.03B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for brain health disorders. Its pipeline includes MM120, in Phase 3 for generalized anxiety disorder and attention deficit hyperactivity disorder, and MM402, in Phase 1 for core symptoms of autism spectrum disorder.

Valuation — source: SEC EDGAR (first-party)
Price$44.88
Market Cap$6.03B
Price / Book6.56
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderJupiter Topco LLC ($264.00M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEORobert Barrow
Employees74
CountryUS
IPO Date2026-01-06

Related Companies (Business model: Branded Consumer (CPG, Staples, Beauty, Alcohol, Pet, Nicotine); 8 closest by market cap; US-domiciled)

  • RPM International Inc. (RPM)
  • The Clorox Company (CLX)
  • Axalta Coating Systems Ltd. (AXTA)
  • e.l.f. Beauty, Inc. (ELF)
  • Inter Parfums, Inc. (IPAR)
  • Coty Inc. (COTY)
  • Niagen Bioscience Inc (NAGE)
  • USANA Health Sciences, Inc. (USNA)
DFTX earnings history · DFTX institutional & insider holders · DFTX KPIs & operating metrics · DFTX financials · DFTX investor presentations & press releases · DFTX SEC filings · DFTX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.